251 related articles for article (PubMed ID: 27919043)
1. Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.
Carraro DM; Elias EV; Andrade VP
Biosci Rep; 2014 Feb; 34(1):. PubMed ID: 27919043
[TBL] [Abstract][Full Text] [Related]
2. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
3. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ: morphology-based knowledge and molecular advances.
Ross DS; Wen YH; Brogi E
Adv Anat Pathol; 2013 Jul; 20(4):205-16. PubMed ID: 23752083
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
6. Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.
Hophan SL; Odnokoz O; Liu H; Luo Y; Khan S; Gradishar W; Zhou Z; Badve S; Torres MA; Wan Y
Endocrinology; 2022 Apr; 163(4):. PubMed ID: 35245349
[TBL] [Abstract][Full Text] [Related]
7. Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics.
Hulahan TS; Spruill L; Wallace EN; Park Y; West RB; Marks JR; Hwang ES; Drake RR; Angel PM
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928454
[TBL] [Abstract][Full Text] [Related]
8. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer.
Doebar SC; Sieuwerts AM; de Weerd V; Stoop H; Martens JWM; van Deurzen CHM
Am J Pathol; 2017 Jul; 187(7):1648-1655. PubMed ID: 28634007
[TBL] [Abstract][Full Text] [Related]
9. Progression from ductal carcinoma in situ to invasive breast cancer: revisited.
Cowell CF; Weigelt B; Sakr RA; Ng CK; Hicks J; King TA; Reis-Filho JS
Mol Oncol; 2013 Oct; 7(5):859-69. PubMed ID: 23890733
[TBL] [Abstract][Full Text] [Related]
10. miRNAs as Biomarkers for Predicting the Progression of Ductal Carcinoma in Situ.
Hannafon BN; Ding WQ
Am J Pathol; 2018 Mar; 188(3):542-549. PubMed ID: 29246496
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer.
Afghahi A; Forgó E; Mitani AA; Desai M; Varma S; Seto T; Rigdon J; Jensen KC; Troxell ML; Gomez SL; Das AK; Beck AH; Kurian AW; West RB
Breast Cancer Res; 2015 Aug; 17(1):108. PubMed ID: 26265211
[TBL] [Abstract][Full Text] [Related]
12. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ: a disease entity that merits more recognition.
Dereere E; Papadimitriou K; Tjalma W; Altintas S
Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
[TBL] [Abstract][Full Text] [Related]
14. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.
Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK
Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623
[TBL] [Abstract][Full Text] [Related]
15. Ductal carcinoma in situ: to treat or not to treat, that is the question.
van Seijen M; Lips EH; Thompson AM; Nik-Zainal S; Futreal A; Hwang ES; Verschuur E; Lane J; Jonkers J; Rea DW; Wesseling J;
Br J Cancer; 2019 Aug; 121(4):285-292. PubMed ID: 31285590
[TBL] [Abstract][Full Text] [Related]
16. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma in situ: biology, diagnosis, and new therapies.
Valenzuela M; Julian TB
Clin Breast Cancer; 2007 Aug; 7(9):676-81. PubMed ID: 17919347
[TBL] [Abstract][Full Text] [Related]
18. Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery.
Langhans L; Jensen MB; Talman MM; Vejborg I; Kroman N; Tvedskov TF
JAMA Surg; 2017 Apr; 152(4):378-384. PubMed ID: 28002557
[TBL] [Abstract][Full Text] [Related]
19. Genomic landscape of ductal carcinoma in situ and association with progression.
Lin CY; Vennam S; Purington N; Lin E; Varma S; Han S; Desa M; Seto T; Wang NJ; Stehr H; Troxell ML; Kurian AW; West RB
Breast Cancer Res Treat; 2019 Nov; 178(2):307-316. PubMed ID: 31420779
[TBL] [Abstract][Full Text] [Related]
20. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
